We have developed a first-in-class therapeutical approach to tackle some of the world’s most intractable diseases.
We are engineering circular RNAs that target structural elements in the RNA that are crucial for the development of disease and combining them with state-of-the-art delivery techniques. Our technology is based on the research from the Molecular Virology Group of Universitat Pompeu Fabra.
Our multidisciplinary team is committed to bring our technology to the hands of those who need it the most, the patients. Throughout this amazing journey, we also count with the support of our excellent Advisory Board.